Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Zacks Investment Research on MSN
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report third-quarter 2025 results on Oct. 30, before market ...
Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback